Tirzepatide Beats TRT for Hypogonadism & Obesity
Tirzepatide Shows Promising Results in Improving Erectile Dysfunction in Obese Men
Table of Contents
New research suggests the GLP-1 receptor agonist may offer importent benefits beyond weight loss for men with obesity and erectile dysfunction (ED).
By Miriam E. Tucker
Obese men experiencing erectile dysfunction (ED) may find a new therapeutic avenue in tirzepatide, a dual GLP-1 and GIP receptor agonist. A recent study presented at an endocrinology conference indicated that tirzepatide not only led to substantial weight loss but also demonstrated notable improvements in ED symptoms, possibly surpassing the effects of testosterone therapy in some aspects.
Tirzepatide Outperforms Lifestyle and Testosterone in Key Metrics
The study, which compared tirzepatide, lifestyle modifications alone, and transdermal testosterone in men with ED and obesity, revealed compelling outcomes after a 2-month treatment period. All participants were instructed to follow a low-calorie diet and engage in 20 minutes of brisk walking daily.
Baseline Characteristics Highlight Differences
At the outset, all 28 participants presented with ED, with International Index of Erectile function (IIEF-5) scores ranging from 5 to 12, indicating moderate to severe ED in at least half of each group. Significant baseline differences were observed: the no-treatment group had a higher waist circumference, while the tirzepatide-treated group exhibited higher scores on the Binge Eating Scale (BES), greater percentage lean mass, and elevated luteinizing hormone (LH) levels.
Significant Weight Loss and Metabolic Improvements with Tirzepatide
The results after 2 months were striking. The tirzepatide group achieved significantly greater improvements in body weight (-8.1%) compared to the lifestyle-only group (-2.4%) and the testosterone group (-3.0%). This superior weight loss extended to BMI, waist circumference, and fat mass. Moreover, the tirzepatide group saw a significant reduction in their BES scores, suggesting a positive impact on binge eating behaviors.
While tirzepatide also led to a greater increase in lean mass compared to the lifestyle-alone group, the difference was not statistically significant when compared to the testosterone group.
Hormonal and Erectile function Benefits
All treatment groups showed reductions in insulin resistance, with both pharmacological interventions yielding greater improvements than lifestyle changes alone.Notably, the tirzepatide group experienced a more substantial increase in IIEF-5 scores compared to the lifestyle-only group. While the increase was also higher than in the testosterone group, this difference did not reach statistical significance.
Hormonal profile Shifts with Tirzepatide
Tirzepatide treatment was associated with significant increases in LH, follicle-stimulating hormone (FSH), and total testosterone levels compared to the other groups.Conversely, 17β-estradiol (E₂) levels were significantly lower with tirzepatide. the testosterone-treated group showed more modest changes across most parameters, including a slight increase in E₂ levels.
Expert Commentary: Beyond Weight loss
Maja Stefanovic-Racic, MD, phd, associate professor of medicine at the University of Pittsburgh School of Medicine, expressed her enthusiasm for tirzepatide’s impact on ED. “I was very impressed that the GLP-1 improved erectile dysfunction, as we certainly know that especially in obese men, adding testosterone frequently enough does not improve ED at all,” she commented. “This may relate to endothelial function outside of weight.”
Echoing this sentiment, the study’s authors, including Cannarella, suggested that weight loss might not be the sole driver of these improvements. “While weight loss undoubtedly plays a major role, the magnitude and speed of hormonal recovery – along with increases in gonadotropins (LH, FSH) and SHBG [sex hormone-binding globulin] – suggest that tirzepatide may exert additional regulatory effects on the hypothalamic-pituitary-gonadal axis,” they noted.
From an endocrinologist’s perspective,Klindukhova stated,”if there’s a patient who is open to it,I would personally go for GLP-1 over testosterone.”
The findings suggest that tirzepatide could represent a valuable therapeutic option for obese men with ED, offering benefits that extend beyond simple weight reduction by positively influencing hormonal balance and potentially improving endothelial function.
Cannarella, Klindukhova, and Stefanovic-Racic have no disclosures.